Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.

Nurmikko, P; Pettersson, K; Piironen, T; Hugosson, J; Lilja, H

Abstract:

BACKGROUND: The proportion of free prostate-specific antigen (PSA) is higher in the sera of patients with benign prostatic hyperplasia compared with patients with prostate cancer (PCa). We developed an immunoassay that measures intact, free PSA forms (fPSA-I), but does not detect free PSA that has been internally cleaved at Lys145-Lys146 (fPSA-N), and investigated whether this form could discriminate patients with PCa from those without PCa. METHODS: The assay for fPSA-I uses a novel monoclon...

Expand abstract

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Nurmikko, P., Pettersson, K., Piironen, T., Hugosson, J., & Lilja, H. (2001). Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clinical Chemistry, 47(8), 1415–1423.

MLA Style

Nurmikko, P., et al. “Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-Specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146.” Clinical Chemistry, vol. 47, no. 8, 2001, pp. 1415–23.

Chicago Style

Nurmikko, P, K Pettersson, T Piironen, J Hugosson, and H Lilja. 2001. “Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-Specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146.” Clinical Chemistry 47 (8): 1415–23.
Tweet
Print